Deschide articolul original într-un tab nou Schimbarea acestei opțiuni se aplică imediat și reîncarcă pagina.
LECTURA
← Înapoi la Urmăritori

Chaotropy

www.chaotropy.com/rss/
Vizitează site-ul

Cel mai recent articol

Ultima verificare

Urmăritori 0 urmăritori
Articole: 15

  1. Why CUE-221 Might Not Beat Omalizumab In CSU And Could Still Separate In Food Allergy

    (Chaotropy)

    Disclosure: The author holds a beneficial long position in Cue Biopharma (NASDAQ: CUE) and no position in any other company mentioned.

  2. Non-Physical Intelligence Has A Ceiling

    (Chaotropy)

    Disclosure: This article is for informational and entertainment purposes only and is not financial advice.

  3. Early Results Of Verastem's VS-7375 In Pancreatic Cancer, Or How To Read A Reduction In CA19-9

    (Chaotropy)

    Disclosure: The author holds a beneficial long position in Verastem Oncology, Inc.

  4. Palantir Is Building The "Brain of The Firm" Envisioned Half a Century Ago

    (Chaotropy)

    Disclosure: The author holds a beneficial long position in Palantir Technologies Inc.

  5. Innovation: America's Perpetual Frontier

    (Chaotropy)

    Pessimism is often mistaken for critical thinking.

  6. Nektar's Rezpegaldesleukin: Aiming To Restore Peripheral Immune Balance

    (Chaotropy)

    Disclosure: The author holds a beneficial long position in Nektar Therapeutics, Inc.

  7. Why Licensing A Dual-Mechanism Anti-IgE Antibody Could Be A Major Opportunity For Cue Biopharma

    (Chaotropy)

    Disclosure: The author holds a beneficial long position in Cue Biopharma, Inc.

  8. Mufemilast Phase 2 Data May Partially De-Risk Palisade Bio's PALI-2108

    (Chaotropy)

    Disclosure: The author holds a beneficial long position in Palisade Bio, Inc.

  9. A Nature Medicine Paper Linking Picloram To Early-Onset Colorectal Cancer Leaves An Open Question

    (Chaotropy)

    A recent Nature Medicine paper by Maas et al., covered on the All-In Podcast, links the herbicide picloram to early-onset colorectal cancer (EOCRC).

  10. Computational Simulation Of Four Non-Covalent KRAS G12D Inhibitors Suggests Verastem's VS-7375 May Achieve The Deepest Signaling Suppression

    (Chaotropy)

    Disclosure: The author holds beneficial long positions in Revolution Medicines, Inc.

  11. Phase 3 Readout Of Daraxonrasib In 2L Metastatic PDAC Marks An Inflection Point For Pancreatic Cancer

    (Chaotropy)

    Disclosure: The author holds beneficial long positions in Revolution Medicines, Inc.

  12. Revisiting My PALI-2108 Tissue Penetration Model In Fibrostenotic Crohn's Disease After Phase 1b Readout

    (Chaotropy)

    Disclosure: The author holds a beneficial long position in Palisade Bio, Inc.

  13. Pharmacokinetic Simulation Of Tenax's Oral Levosimendan Suggests Higher Drug Exposure Than IV Dosing In PH-HFpEF

    (Chaotropy)

    Disclosure: The author holds a beneficial long position in Tenax Therapeutics, Inc.

  14. Johns Hopkins mKRAS Vaccine Trial Strengthens The Case For Elicio's ELI-002

    (Chaotropy)

    Disclosure: The author holds a beneficial long position in Elicio Therapeutics (NASDAQ: ELTX).

  15. Monte Carlo Simulation Of Elicio's Phase II AMPLIFY-7P Study Favors Vaccine Efficacy

    (Chaotropy)

    Disclosure: The author holds a beneficial long position in Elicio Therapeutics, Inc.